The European Reference Networks are featured in the Commission's EU Protects campaign which aims to raise awareness of the ways in which the EU combats global challenges to protect its citizens.Watch here a moving video about the ERN for rare epilepsies which explains what the ERNs do.
The background of this videoAs many as 8,000 rare diseases affect the lives of around 30 million people in the EU every day. Many of those affected by a rare or complex disease do not have access to diagnosis and high-quality treatment, since no country alone has the knowledge and capacity to treat all rare diseases and conditions. European Reference Networks (ERNs) are virtual knowledge-sharing networks involving healthcare providers across Europe. These networks give patients and doctors across the EU access to the best expertise, while facilitating the timely exchange of life-saving knowledge, often without the need to travel to another country. The EpiCARE network brings together 28 highly specialised health centers in 13 European countries, all of whom have expertise in rare and complex forms of epilepsy.
The storyLast year, EpiCARE took on the case of a 4-year-old Finnish boy with a rare abnormality in the brain, causing him to have between 20-30 seizures each day. This was a very specific disorder of which only a small number of medical centres in the world have experience. A decision therefore had to be made on what kind of treatment to suggest – Gamma Knife® surgery, only available in 2 centres, or surgical resection, only performed in 3-4 centres. The doctors in Finland presented the case to the network, with 7 other countries present (Italy, UK, France, Spain, Romania, Sweden, and the Netherlands). After reviewing the different treatment options, it was decided that the child should go to Marseille for Gamma Knife surgery®. The surgery was successful, and although the boy still experiences seizures, their number has been drastically reduced.
The objectiveThe story aims to introduce readers to the principle of European Reference Networks and the value of the knowledge sharing they enable. Through the story of this particular young patient, audiences will understand that cooperation at an EU level makes a real difference to both patients and their families, as well as to the health professionals that care for them. Due to the rarity of such complex conditions specialist knowledge is scarce, fragmented and often not available in the patient's region or even country. Many patients therefore do not get satisfactory explanations for their symptoms and have difficulties finding a specialist with the necessary knowledge about treatment options. By consolidating knowledge and expertise scattered across countries, the ERNs give healthcare providers access to a much larger pool of expertise. This story demonstrates that the ERNs improve the chances of patients receiving accurate diagnoses and advice on the best treatment for their condition.
The European reference networksEuropean Reference Networks (ERNs) are unique and innovative cross-border cooperation platforms
that enable specialists to diagnose and treat rare or low prevalence diseases. They aim to provide highly specialised treatment and to concentrate knowledge and resources. ERNs are being set up under the EU Directive on Patients' Rights in Healthcare (2011/24/EU), which also makes it easier for patients to access information on healthcare and increase their treatment options. There are 24 ERNs involving 25 European countries (including Norway) and more than 300 hospitals with over 900 healthcare units covering all major disease groups. These 24 specialised networks are working on a range of medical issues including bone disorders, childhood cancer and immunodeficiency. The ERN initiative receives support from several EU funding programs, including the Health Programme, the Connecting Europe Facility and Horizon 2020.
Related news items
Valentine’s day spectacle at the Radboud Research Rounds21 February 2019
This year’s Valentine’s day in the Radboudumc was focused on the RRR of the Tumors of the Digestive Tract. In the biannual Paper Award session the big prize went to Daniel Garza from the Center for Molecular and Biomolecular Informatics, for his paper on “the environmental metabolome”.read more
New infection route resistant hospital bacteria discovered21 February 2019
In a case study on JAMA Network Open, physician microbiologist Joost Hopman describes how the rare bacterium Pseudomonas aeruginosa could spread infection from shower drains in patient rooms.read more
Optimal dosing of anti-HIV drug darunavir in pregnant women21 February 2019
In the Journal of Antimicrobial Chemotherapy Stein Schalkwijk, Rob ter Heine, Angela Colbers and David Burger investigated how pregnant women should be treated with the anti-HIV drug darunavir.read more
Celebrations to mark the retirement of Joost Schalkwijk21 February 2019
With a mini symposium (‘Oppervlakkig en toch diepgaand’) and reception a passionate researcher of the RIMLS said farewell. After 36 working years Joost Schalkwijk, theme Inflammatory diseases, will enjoy his retirement.read more
Ultrahigh-resolution MRI reveals structural brain differences in serotonin transporter knockout rats after sucrose and cocaine self-administration20 February 2019
In Addiction Biology Peter Karel and Judith Homberg showed that rats lacking the serotonin transporter show increased cocaine, but unaltered sucrose, self-administration.read more